Daiwa Securities Group
RARE icon

Daiwa Securities Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Daiwa Securities Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160K Buy
7,660
+381
+5% +$8.58K ﹤0.01% 1035
2025
Q4 		$168K Buy
7,279
+371
+5% +$12.2K ﹤0.01% 1009
2025
Q3 		$208K Buy
6,908
+6,568
+1,932% +$197K ﹤0.01% 980
2025
Q2 		$12K Buy
340
+35
+11% +$1.26K ﹤0.01% 1115
2025
Q1 		$11K Hold
305
– – ﹤0.01% 1090
2024
Q4 		$13K Sell
305
-45
-13% -$2.23K ﹤0.01% 1105
2024
Q3 		$19K Buy
350
+46
+15% +$2.34K ﹤0.01% 1101
2024
Q2 		$12K Hold
304
– – ﹤0.01% 1156
2024
Q1 		$14K Sell
304
-32
-10% -$1.51K ﹤0.01% 1151
2023
Q4 		$16K Buy
336
+54
+19% +$2.09K ﹤0.01% 1144
2023
Q3 		$10K Hold
282
– – ﹤0.01% 1127
2023
Q2 		$13K Hold
282
– – ﹤0.01% 1128
2023
Q1 		$11K Hold
282
– – ﹤0.01% 1107
2022
Q4 		$13K Buy
282
+21
+8% +$826 ﹤0.01% 1102
2022
Q3 		$11K Hold
261
– – ﹤0.01% 1122
2022
Q2 		$16K Buy
261
+62
+31% +$3.81K ﹤0.01% 1122
2022
Q1 		$14K Hold
199
– – ﹤0.01% 1126
2021
Q4 		$17K Sell
199
-33
-14% -$2.69K ﹤0.01% 1125
2021
Q3 		$21K Buy
232
+99
+74% +$8.95K ﹤0.01% 1101
2021
Q2 		$13K Hold
133
– – ﹤0.01% 1035
2021
Q1 		$15K Buy
133
+9
+7% +$1.23K ﹤0.01% 1024
2020
Q4 		$17K Sell
124
-216
-64% -$25.6K ﹤0.01% 989
2020
Q3 		$28K Buy
340
+14
+4% +$1.16K ﹤0.01% 968
2020
Q2 		$14K Hold
326
– – ﹤0.01% 1048
2020
Q1 		$14K Hold
326
– – ﹤0.01% 1036
2019
Q4 		$14K Sell
326
-32
-9% -$1.32K ﹤0.01% 1037
2019
Q3 		$15K Hold
358
– – ﹤0.01% 1009
2019
Q2 		$23K Hold
358
– – ﹤0.01% 1002
2019
Q1 		$25K Buy
358
+98
+38% +$5.6K ﹤0.01% 982
2018
Q4 		$11K Hold
260
– – ﹤0.01% 993
2018
Q3 		$20K Hold
260
– – ﹤0.01% 1003
2018
Q2 		$20K Hold
260
– – ﹤0.01% 1010
2018
Q1 		$13K Buy
+260
New +$13.1K ﹤0.01% 1013

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Daiwa Securities Group's RARE Position: Q1 2026 in Review

Daiwa Securities Group increased its Ultragenyx Pharmaceutical (RARE) stake by 5.2% in Q1 2026, buying an estimated $8.58K and bringing the position to 7,660 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #1035.

Daiwa Securities Group first reported a position in RARE in Q1 2018 and has held it in 33 quarters since. The position peaked at $208K in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Daiwa Securities Group held 7,660 shares of Ultragenyx Pharmaceutical worth $160K as of Q1 2026.
  • Daiwa Securities Group bought 381 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $8.58K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Daiwa Securities Group's portfolio in Q1 2026, its #1035 holding.
  • Daiwa Securities Group first reported a position in Ultragenyx Pharmaceutical in Q1 2018 and has held it in 33 quarters since.
  • Daiwa Securities Group's Ultragenyx Pharmaceutical position peaked at $208K in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.